Standard Standard

HarvardHarvard

Stuart, NS, von Minckwitz, G, Chernozemsky, I, Sirakova, L, Chilingirov, P, Souchon, R, Marschner, N, Kleeberg, U, Tsekov, C, Fritze, D, Thomssen, CF, Stuart, N, Vermorken, JB, Loibl, S, Merkle, KH & Kaufmann, M 2005, 'Bendamustine prolongs progression-free survival in metastatic breast cancer (MBC): a phase III prospective, randomized, multicenter trial of bendamustine hydrochloride, methotrexate and 5-fluorouracil (BMF) versus cyclophosphamide, methotrexate and 5-fluorouracil (CMF) as first-line treatment of MBC', Anti-Cancer Drugs, vol. 16, no. 8, pp. 871-877.

APA

Stuart, N. S., von Minckwitz, G., Chernozemsky, I., Sirakova, L., Chilingirov, P., Souchon, R., Marschner, N., Kleeberg, U., Tsekov, C., Fritze, D., Thomssen, C. F., Stuart, N., Vermorken, J. B., Loibl, S., Merkle, K. H., & Kaufmann, M. (2005). Bendamustine prolongs progression-free survival in metastatic breast cancer (MBC): a phase III prospective, randomized, multicenter trial of bendamustine hydrochloride, methotrexate and 5-fluorouracil (BMF) versus cyclophosphamide, methotrexate and 5-fluorouracil (CMF) as first-line treatment of MBC. Anti-Cancer Drugs, 16(8), 871-877.

CBE

MLA

VancouverVancouver

Author

RIS

TY - JOUR

T1 - Bendamustine prolongs progression-free survival in metastatic breast cancer (MBC): a phase III prospective, randomized, multicenter trial of bendamustine hydrochloride, methotrexate and 5-fluorouracil (BMF) versus cyclophosphamide, methotrexate and 5-fluorouracil (CMF) as first-line treatment of MBC

AU - Stuart, N.S.

AU - von Minckwitz, G.

AU - Chernozemsky, I.

AU - Sirakova, L.

AU - Chilingirov, P.

AU - Souchon, R.

AU - Marschner, N.

AU - Kleeberg, U.

AU - Tsekov, C.

AU - Fritze, D.

AU - Thomssen, C.F.

AU - Stuart, N.

AU - Vermorken, J.B.

AU - Loibl, S.

AU - Merkle, K.H.

AU - Kaufmann, M.

PY - 2005/9/1

Y1 - 2005/9/1

M3 - Article

VL - 16

SP - 871

EP - 877

JO - Anti-Cancer Drugs

JF - Anti-Cancer Drugs

SN - 0959-4973

IS - 8

ER -